Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Name: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
Published: 2025
License: Public Domain

First Affiliated Hospital of Zhejiang University · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

breastcancer hr immunotherapy negative

hr+/her2- breast cancer, breast cancer, toripalimab, adjuvant chemotherapy, immunotherapy, hr-positive her2-negative, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Related documents